<i>In vitro</i> activities of aztreonam/nacubactam and cefepime/nacubactam against a global collection of molecularly characterized Enterobacterales isolates carrying carbapenemases: a global antimicrobial resistance surveillance study from 2021 to 2023. [PDF]
Estabrook M +3 more
europepmc +1 more source
Cefepime Induced Neurotoxicity
Neurotoxicity is well established in current literature as a known adverse effect of cefepime antibiotic therapy. This is suspected to be secondary to cefepime’s ability to penetrate into the central nervous system. In the setting of renal insults, there
Thompson, Jeff +3 more
core
Cefepime 2.0: Upgrading β-Lactamase Inhibitor Use. [PDF]
De Rosa FG +6 more
europepmc +1 more source
Delayed-Onset Cefepime Neurotoxicity in a Patient With Epilepsy and ESRD. [PDF]
Omojola O +6 more
europepmc +1 more source
Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy. [PDF]
Eckmann C +16 more
europepmc +1 more source
Cefepime-Induced Delirium in a Patient With Chronic Kidney Disease: A Case Report. [PDF]
Gomes H, Pires M, Freitas C, Freitas RM.
europepmc +1 more source
Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat <i>Pseudomonas aeruginosa</i> clinical isolates. [PDF]
Mystakelis H +7 more
europepmc +1 more source
Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters. [PDF]
Gregoire M +6 more
europepmc +1 more source
Antibiotic development and a path to access in India. [PDF]
Manesh A +4 more
europepmc +1 more source
Cefepime and Mortality: A Systematic Review and Bayesian Meta-Analysis.
Sohani ZN +15 more
europepmc +1 more source

